SecBot SecBot
PRESS-RELEASE ·Filed May 13, 2026

ABEO

Abeona Therapeutics Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Revenue growth trajectory and QTC expansion are positive, but cash burn and widening losses keep the stock binary on ZEVASKYN adoption. Watch for Q2 2026 patient treatment numbers and any ABO-701 IND timeline updates. The EPS beat vs consensus may provide a short-term lift, but sustained commercial execution is needed for a fundamental re-rating.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.71
T+0 close · May 13, 2026 · via day close
Latest settled
+26.80%
T+60 · $7.24
Vs SPY
+22.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $5.71entry
  2. T+1 · 6mo ago −1.93%α −2.70% · $5.60
  3. T+5 · 6mo ago −10.33%α −9.17% · $5.12
  4. T+20 · 5mo ago −3.15%α −2.54% · $5.53
  5. T+60 · 3mo ago +26.80%α +22.36% · $7.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abeona reported Q1 2026 net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025, with three patients treated. Net loss widened to $(17.1)M ($(0.30)/share) from $(12.0)M a year ago, driven by SG&A ramp-up and a $7.0M licensing payment for ABO-701. Cash burn and lack of profitability keep the stock in speculative territory despite commercial progress.

Key Financial Metrics

EPS
−$0.30
est −$0.39 · +23.1%
Revenue
$8.7M
est $4.9M · +78.0%
Rating
in line
Gross Margin
69.08%

Key Facts

  • Q1 2026 net product revenue $8.7M (vs $2.4M Q4 2025, $0 in Q1 2025)
  • Net loss $(17.1)M or $(0.30)/share vs $(12.0)M or $(0.24)/share in Q1 2025
  • Cash, equivalents & short-term investments $168.3M as of March 31, 2026 (down from $191.4M Dec 31, 2025)
  • Three patients treated with ZEVASKYN in Q1 2026; QTC network expanded to six sites
  • In-licensed ABO-701 (PSMA-SIR-T) for prostate cancer; IND expected H2 2027
  • Ophthalmology programs deprioritized
  • EPS $(0.30) vs consensus $(0.39), a 23% beat on a GAAP basis

Financial Impact

Q1 2026 product revenue $8.7M; net loss $(17.1)M; cash burn ~$23M in the quarter

revenuenet losscash position

Risk Factors

  • Cash burn rate of ~$23M/quarter implies ~7 quarters of runway at current spend
  • ZEVASKYN adoption still early, only 3 patients treated in Q1; revenue concentration risk
  • ABO-701 is preclinical; IND not expected until H2 2027, no near-term catalyst
  • Accumulated deficit of $(759)M with no path to profitability visible

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293883

Track record

29 reports on ABEO

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  5. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
  6. Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
  7. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
  8. Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
  9. Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
  10. Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (10h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026